Alpha Cognition Valuation Multiples

Alpha Cognition Overview

About Alpha Cognition

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited or no treatment options. The Company’s current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company’s commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Founded

2017

HQ

Employees

57

Website

alphacognition.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $14M

Net Income: ($21M)

EV

$78M

Valuation Multiples

Multiples.vc

Start free trial

Alpha Cognition Financials

Alpha Cognition reported last 12-month revenue of $14M.

In the same LTM period, Alpha Cognition generated $12M in gross profit and had net loss of ($21M).

Alpha Cognition P&L

In the most recent fiscal year, Alpha Cognition reported revenue of — and EBITDA of ($14M).

Alpha Cognition expects next 12-month revenue of XXX and NTM EBITDA of XXX

Alpha Cognition Stock Performance

Alpha Cognition has current market cap of $126M, and enterprise value of $78M.

Alpha Cognition's stock price is $5.79.

Alpha Cognition Valuation Multiples

Alpha Cognition trades at 5.7x EV/Revenue multiple, and (5.4x) EV/EBITDA.

Alpha Cognition Financial Valuation Multiples

As of March 18, 2026, Alpha Cognition has market cap of $126M and EV of $78M.

Equity research analysts estimate Alpha Cognition's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Alpha Cognition has a P/E ratio of (5.9x).

Alpha Cognition Margins & Growth Rates

Alpha Cognition's revenue in the last 12 month grew by 82%.

Alpha Cognition's revenue per employee in the last FY averaged $0.2M.

Alpha Cognition Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Alpha Cognition M&A Activity

Alpha Cognition acquired XXX companies to date.

Last acquisition by Alpha Cognition was on XXXXXXXX, XXXXX. Alpha Cognition acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Alpha Cognition Investment Activity

Alpha Cognition invested in XXX companies to date.

Alpha Cognition made its latest investment on XXXXXXXX, XXXXX. Alpha Cognition invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).